Mirtazapine Mylan (Mirtazapine)

Mirtazapine works by blocking central presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonizing 5‑HT2 and 5‑HT3 serotonin receptors. This dual action raises levels of norepinephrine and serotonin in the brain, contributing to its antidepressant effect.

The appropriate dose of Mirtazapine Mylan is determined by the prescribing healthcare professional based on the individual’s clinical condition, response to therapy, and tolerability. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of mirtazapine in pregnancy and lactation has not been definitively established. Healthcare providers weigh potential benefits against possible risks before prescribing it to pregnant or nursing women, and alternative treatments may be considered.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapine differs from many selective serotonin reuptake inhibitors (SSRIs) by also enhancing norepinephrine release and by its antagonism of certain serotonin receptors, which can lead to a distinct side‑effect profile such as increased appetite and sedation. Choice of therapy depends on patient‑specific factors and clinician judgment.

Mirtazapine Mylan tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Mirtazapine Mylan is taken orally, usually once daily in the evening with or without food, as directed by the prescriber. Swallow the tablet whole; do not crush or chew unless specifically instructed.

Serious risks include the potential for severe neutropenia or agranulocytosis, significant liver enzyme elevations indicating hepatic injury, and the emergence or worsening of suicidal thoughts, particularly early in treatment or when dose changes occur.

Mirtazapine is contraindicated in patients who have taken a monoamine oxidase inhibitor (MAOI) within the past 14 days, or in individuals with known hypersensitivity to mirtazapine or any of its excipients. Caution is also advised for patients with severe hepatic impairment.